Acquisition SynergiesTMO's acquisition of Clario is a strategic fit that enhances their clinical trial offerings and is expected to be accretive to margins and earnings per share.
Financial PerformanceThermo Fisher reported continuously improved financials for 3Q25, with revenue increasing by 5.0% YoY and adjusted EPS rising by 9.7% YoY.
Reshoring InitiativesThermo Fisher is well-positioned to benefit from the trend of onshore manufacturing in the US, with its businesses expected to capture incremental demand from increased manufacturing capacity.